Captor Therapeutics, a biopharmaceutical company dedicated to the development of targeted protein degradation (TPD)-based drugs for the treatment of cancer and autoimmune diseases, has selected CPT-6281 as drug candidate for the CT-01 project, which will initially focus on the clinical development of the asset as a TPD treatment against hepatocellular carcinoma (HCC). The announcement of the drug candidate confirms that CPT-6281 is on track to enter the clinical phase in 2023. As disclosed ea...